FDA Approves Capivasertib with Fulvestrant for Breast Cancer
Evidence for efficacy is evaluated in CAPItello-291 study
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Evidence for efficacy is evaluated in CAPItello-291 study
Final results of a preplanned analysis at a 10-year follow-up of H10 study
Findings from an exploratory post hoc analysis of the subgroup of patients with BRCA alterations in PROfound study
Evidence for efficacy is based on the results from the FRESCO-2 and FRESCO studies
It is intended for the treatment of adults with advanced NSCLC with KRAS G12C mutation and disease progression after at least one prior systemic therapy
Findings from the IMbrave050 study
A new method developed to measure the antibody levels against PD-1
Findings from the DUO-E study
Evidence for efficacy is based on the results from the JUPITER-02 and POLARIS-02 studies
Findings from an individual patient data meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group could reflect radiotherapy improvements
It also approved a companion diagnostic device to select patients for the treatment with ivosidenib
Evidence for efficacy is based on the results from the KEYNOTE-966 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.